[go: up one dir, main page]

MX2023013791A - Composiciones que comprenden una terapéutica de redirección de células t y una terapéutica anti-cd44. - Google Patents

Composiciones que comprenden una terapéutica de redirección de células t y una terapéutica anti-cd44.

Info

Publication number
MX2023013791A
MX2023013791A MX2023013791A MX2023013791A MX2023013791A MX 2023013791 A MX2023013791 A MX 2023013791A MX 2023013791 A MX2023013791 A MX 2023013791A MX 2023013791 A MX2023013791 A MX 2023013791A MX 2023013791 A MX2023013791 A MX 2023013791A
Authority
MX
Mexico
Prior art keywords
therapeutic
compositions
cell redirection
cell
redirection
Prior art date
Application number
MX2023013791A
Other languages
English (en)
Inventor
Francois Gaudet
Bradley J Heidrich
Priyanka Nair-Gupta
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of MX2023013791A publication Critical patent/MX2023013791A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente descripción se describe una composición farmacéutica que comprende una terapéutica de redirección de células T y una terapéutica anti-CD44, y usos de estas para destruir células cancerosas.
MX2023013791A 2021-05-18 2022-05-16 Composiciones que comprenden una terapéutica de redirección de células t y una terapéutica anti-cd44. MX2023013791A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163189737P 2021-05-18 2021-05-18
PCT/IB2022/054529 WO2022243838A1 (en) 2021-05-18 2022-05-16 Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic

Publications (1)

Publication Number Publication Date
MX2023013791A true MX2023013791A (es) 2024-02-13

Family

ID=81854798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013791A MX2023013791A (es) 2021-05-18 2022-05-16 Composiciones que comprenden una terapéutica de redirección de células t y una terapéutica anti-cd44.

Country Status (10)

Country Link
US (1) US20240228618A1 (es)
EP (1) EP4340942A1 (es)
JP (1) JP2024518200A (es)
KR (1) KR20240008345A (es)
CN (1) CN117396226A (es)
AU (1) AU2022278013A1 (es)
BR (1) BR112023024209A2 (es)
CA (1) CA3220458A1 (es)
MX (1) MX2023013791A (es)
WO (1) WO2022243838A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
CN119614511A (zh) * 2024-12-20 2025-03-14 华南理工大学 一种改造hl60细胞的构建方法及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
JP2007510735A (ja) 2003-11-07 2007-04-26 ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド Ｃｄ４４グリコフォームに対する抗体およびその使用
EP1532984A1 (en) 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
PT2558499T (pt) 2010-04-16 2017-07-14 Biogen Ma Inc Anticorpos anti-vla-4
KR20140090997A (ko) 2011-10-26 2014-07-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 B-세포 만성 림프구성 백혈병 및 다른 혈액학적 악성종양의 치료를 위한 cd44 단일클론 항체
RS60305B1 (sr) * 2014-09-05 2020-07-31 Janssen Pharmaceutica Nv Agensi koji vezuju cd123 i njihove upotrebe
AU2019270624B2 (en) * 2018-05-16 2024-05-02 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics

Also Published As

Publication number Publication date
EP4340942A1 (en) 2024-03-27
BR112023024209A2 (pt) 2024-01-30
KR20240008345A (ko) 2024-01-18
WO2022243838A1 (en) 2022-11-24
CN117396226A (zh) 2024-01-12
AU2022278013A1 (en) 2024-01-18
JP2024518200A (ja) 2024-04-30
CA3220458A1 (en) 2022-11-24
US20240228618A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
MX2023013791A (es) Composiciones que comprenden una terapéutica de redirección de células t y una terapéutica anti-cd44.
MX2020012679A (es) Compuestos de amino-pirazincarboxamida, conjugados, y usos de los mismos.
WO2019220369A3 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
WO2024073723A3 (en) Anti-cd122 antibodies and uses thereof
EP3949969A3 (en) Benzazepine compounds, conjugates, and uses thereof
BR0307329A (pt) inibidores de cicloalquila da função do canal de potássio
UY27886A1 (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco.
ZA202211405B (en) Anti-cd73-anti-pd-1 bispecific antibody and use thereof
MX2023003448A (es) Composicion farmaceutica que comprende conjugado de anticuerpo-farmaco y uso de la misma.
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
PH12022551468A1 (en) Compounds active towards nuclear receptors
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
WO2021211683A3 (en) Compositions and methods for targeted therapeutic delivery to bone
WO2021038296A3 (en) Modified tff2 polypeptides
EP4353318A3 (en) Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
EP4292606A3 (en) Compositions for treating cancer
GEP20227384B (en) Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment
MX2022014426A (es) Composiciones que comprenden una terapéutica de redirección de células t y un inhibidor de la ruta de adhesión de vla-4.
PH12022553030A1 (en) Pharmaceutical formulations of abiraterone acetate and niraparib
AU2018288712A1 (en) Methods for treating merkel cell carcinoma (MCC) using NK-92 cells
MX2024001889A (es) Compuestos deuterados.
WO2023130146A3 (en) Cellular uptake peptide-therapeutic payload compositions and methods of use
WO2023220626A3 (en) 5t4 binding agents and uses thereof
CA3165524C (en) Benzoselene-based compound, pharmaceutical composition, the container and antibody-drug conjugate
MX2022010593A (es) Composiciones tópicas de diclofenaco y métodos.